Amrutanjan's Q4 EBITDA significantly increased by 44% compared to the same quarter last year, reaching INR 255 million. The company's profit margins also improved, standing at 17.1%, marking a rise of 4 percentage points year-on-year.

Amrutanjan Health Care has named Ramaswami Krishnan as its new Independent Director, serving a five-year tenure from May 2026. Meanwhile, Muralidharan Swayambunathan is set to return for another five-year term, pending shareholder approval, starting in June 2026.

Amrutanjan grants ESOP shares worth over two million rupees to 44 key employees, valued at approximately ₹502 per share, with a five-year vesting period extending until October 2031.

Amrutanjan Health Care has reported a 6.65% increase in their standalone net profit for the fourth quarter of FY26, indicating improved financial performance compared to the previous year.

On May 8, 2026, Amrutanjan Health Care will review their financial results for FY25-26 and propose a final dividend. However, from April 1 to May 10, the trading window for equity shares will be closed as per SEBI PIT Regulations.